Frank Mattner

TREATMENT OF ALZHEIMER'S DISEASE (AD) WITH AN ALUMINUM SALT

#2 | 2020-11-26

US20200369738A1

Treatment of Local Skin Hypotrophy Conditions

#3 | 2020-10-29

US20200338192A1

Treatment of Alzheimer's Disease (AD) with an aluminum salt

#4 | 2020-02-06

US20200038487A1

PREVENTION AND TREATMENT OF NON-MELANOMA SKIN CANCER (NMSC)

#5 | 2017-03-02

US20170056495A1

Treatment of alzheimer'S disease (AD) with an aluminum salt

#6 | 2017-02-23

US20170049812A1

Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxide

#7 | 2017-02-23

US20170049810A1

Treatment and prevention of alzheimer's disease (AD)

#8 | 2016-01-14

US20160008443A1

METHOD FOR TREATING A beta-AMYLOIDOSIS

#9 | 2015-10-29

US20150306194A1

METHOD FOR TREATING A SYNUCLEIOPATHY

#10 | 2015-06-18

US20150166620A1

Method of inhibiting C5a

#11 | 2015-04-02

US20150093432A1

COMPOSITION

#12 | 2015-04-02

US20150093431A1

COMPOSITIONS

#13 | 2014-09-11

US20140255435A1

Vaccine

#14 | 2014-08-28

US20140242727A1

Method for diagnosing alzheimer's disease (AD)

#15 | 2014-08-21

US20140234877A1

METHOD FOR DETECTING A BETA-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE

#16 | 2014-06-26

US20140179900A1

TREATMENT OF ATHEROSCLEROSIS WITH CHOLESTEROL ESTER TRANSPORT PROTEIN MIMOTOPES

#17 | 2013-10-31

US20130287807A1

COMPOUNDS FOR TREATING SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE

#18 | 2013-09-05

US20130230545A1

COMPOUNDS FOR TREATING BETA-AMYLOIDOSES

#19 | 2013-08-22

US20130216583A1

VACCINE COMPOSITION COMPRISING AN ANTIGEN AND A PEPTIDE HAVING ADJUVANT PROPERTIES

#20 | 2013-08-22

US20130216565A1

Methods for inhibiting C5a with C5a peptides coupled or fused to a carrier protein

#21 | 2012-10-25

US20120269836A1

Vaccine

#22 | 2011-12-08

US20110300169A1

Pharmaceutical composition comprising an antigen

#23 | 2011-11-10

US20110275556A1

Treatment of atherosclerosis with cholesterol ester transport protein mimotopes

#24 | 2011-08-18

US20110201987A1

COMBINATION THERAPY FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE, AND KIT THEREFOR

#25 | 2011-04-28

US20110097351A1

Compounds for treating beta-amyloidoses

#26 | 2011-04-21

US20110092436A1

COMPOUNDS FOR TREATING SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE

#27 | 2011-01-20

US20110015131A1

METHODS FOR PREVENTING AND TREATING ALZHEIMER'S DISEASE (AD)

#28 | 2009-05-14

US20090123486A1

Vaccine composition comprising an antigen and a peptide having adjuvant properties

#29 | 2009-04-23

US20090104217A1

Pharmaceutical Composition Comprising An Antigen

#30 | 2009-03-26

US20090081246A1

METHOD FOR ISOLATING HEPATITIS C VIRUS PEPTIDES

#31 | 2009-01-01

US20090004210A1

Method for preventing and treating Alzheimer's disease

#32 | 2008-07-10

US20080166368A1

Method of vaccination comprising administering an antigen and a cathelicidin derived antimicrobial peptide

#33 | 2008-02-28

US20080051690A1

Combination therapy for the treatment of Alzheimer's disease

#34 | 2008-01-31

US20080025996A1

Methods and Compositions Comprising Polycationic Compounds

#35 | 2007-09-20

US20070218073A1

ANTIGENIC COMPOSITION

#36 | 2007-07-17

US10250953

Uses for polycationic compounds

#37 | 2007-06-14

US20070134262A1

Antigens encoded by alternative reading frames from pathogenic viruses

#38 | 2007-02-01

US20070026029A1

Methods of treating Alzheimer's Disease with an apheresis device

#39 | 2006-12-12

US10297497

Antigenic composition

#40 | 2006-09-28

US20060216691A1

Method for isolating hepatitis C virus peptides

#41 | 2006-05-25

US20060111301A1

Methods for preventing and treating Alzheimer's disease

#42 | 2005-10-06

US20050221381A1

Method for isolating ligands

#43 | 2005-07-28

US20050163797A1

Pharmaceutical composition comprising an antigen

#44 | 2005-03-24

US20050063978A1